Status:
COMPLETED
Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING)
Lead Sponsor:
University of Sao Paulo General Hospital
Collaborating Sponsors:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conditions:
Smoking Cessation
Genetic Predisposition
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Smoking is the leading cause of avoidable death in the world. Smoking is associated with the development of cardiovascular and respiratory diseases, as well as being considered a leading cause of canc...
Detailed Description
The patients will be invited to take part in the study collection genetic´s materials in order to determinate the frequency of CHRNA4 AND CYP2B6. The polymorphisms in genes involved in the coding of ...
Eligibility Criteria
Inclusion
- smoking who wants to quit smoking, stable clinic diseases, depression or anxiety disorder stable for more than 3 months
Exclusion
- contra indication for varenicline and or bupropion
- unstable psychiatric disorders.
- In the treatment of neoplastic diseases.
- Limitation to attend the medical visits
Key Trial Info
Start Date :
November 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 15 2022
Estimated Enrollment :
361 Patients enrolled
Trial Details
Trial ID
NCT03362099
Start Date
November 1 2016
End Date
April 15 2022
Last Update
December 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ambulatório de Tratamento Tabagismo - Incor HCFMUSP
São Paulo, Brazil, 05403000